342 related articles for article (PubMed ID: 17764782)
21. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.
Goldberg RB; Fonseca VA; Truitt KE; Jones MR
Arch Intern Med; 2008 Jul; 168(14):1531-40. PubMed ID: 18663165
[TBL] [Abstract][Full Text] [Related]
22. Octreotide treatment for sulfonylurea-induced hypoglycaemia.
Crawford BA; Perera C
Med J Aust; 2004 May; 180(10):540-1; author reply 541. PubMed ID: 15139835
[No Abstract] [Full Text] [Related]
23. Emergency management of oral hypoglycemic drug toxicity.
Rowden AK; Fasano CJ
Emerg Med Clin North Am; 2007 May; 25(2):347-56; abstract viii. PubMed ID: 17482024
[TBL] [Abstract][Full Text] [Related]
24. Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes.
Braatvedt GD
N Z Med J; 1997 May; 110(1044):189-90. PubMed ID: 9201206
[No Abstract] [Full Text] [Related]
25. Octreotide: a novel therapy for refractory sulfonylurea-induced hypoglycemia.
Barkin JA; Block HM; Mendez PE
Pancreas; 2013 May; 42(4):722-3. PubMed ID: 23591434
[No Abstract] [Full Text] [Related]
26. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
Meneghini L; Koenen C; Weng W; Selam JL
Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of sulfonylurea-induced prolonged hypoglycemia with use of octreotide.
Fleseriu M; Skugor M; Chinnappa P; Siraj ES
Endocr Pract; 2006; 12(6):635-40. PubMed ID: 17229659
[TBL] [Abstract][Full Text] [Related]
28. Sulfonylurea intoxication at a tertiary care paediatric hospital.
Glatstein M; Garcia-Bournissen F; Scolnik D; Koren G
Can J Clin Pharmacol; 2010; 17(1):e51-6. PubMed ID: 20124602
[TBL] [Abstract][Full Text] [Related]
29. Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon.
Mohnike K; Blankenstein O; Pfuetzner A; Pötzsch S; Schober E; Steiner S; Hardy OT; Grimberg A; van Waarde WM
Horm Res; 2008; 70(1):59-64. PubMed ID: 18493152
[TBL] [Abstract][Full Text] [Related]
30. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
Gao Y; Guo XH; Vaz JA;
Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
[TBL] [Abstract][Full Text] [Related]
31. Inadvertent sulfonylurea overdosage and hypoglycemia in an elderly woman: failure of serum hypoglycemia screening.
Earle KE; Rushakoff RJ; Goldfine ID
Diabetes Technol Ther; 2003; 5(3):449-51. PubMed ID: 12828829
[TBL] [Abstract][Full Text] [Related]
32. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes.
Jones MR; Mudaliar S; Hernandez-Triana E; Unnikrishnan AG; Lai YL; Abby SL; Misir S; Jin X; Nagendran S
Curr Med Res Opin; 2009 Sep; 25(9):2239-49. PubMed ID: 19622007
[TBL] [Abstract][Full Text] [Related]
33. Pilot study of oral montelukast added to standard therapy for acute asthma exacerbations in children aged 6 to 14 years.
Nelson KA; Smith SR; Trinkaus K; Jaffe DM
Pediatr Emerg Care; 2008 Jan; 24(1):21-7. PubMed ID: 18165796
[TBL] [Abstract][Full Text] [Related]
34. Octreotide for hypoglycemia caused by sulfonylurea and DPP-4 inhibitor.
Yamaguchi S; Ikejima M; Furukawa A; Abe M; Nakazaki M; Ishihara H
Diabetes Res Clin Pract; 2015 Aug; 109(2):e8-e10. PubMed ID: 26025695
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
36. Long-acting sulfonylureas -- long-acting hypoglycaemia.
Veitch PC; Clifton-Bligh RJ
Med J Aust; 2004 Jan; 180(2):84-5. PubMed ID: 14723592
[No Abstract] [Full Text] [Related]
37. Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide.
Lheureux PE; Zahir S; Penaloza A; Gris M
Crit Care; 2005; 9(6):543-9. PubMed ID: 16356235
[TBL] [Abstract][Full Text] [Related]
38. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery.
Oifa S; Sydoruk T; White I; Ekstein MP; Marouani N; Chazan S; Skornick Y; Weinbroum AA
Clin Ther; 2009 Mar; 31(3):527-41. PubMed ID: 19393843
[TBL] [Abstract][Full Text] [Related]
39. Octreotide therapy for recurrent refractory hypoglycemia due to sulfonylurea in diabetes-related kidney failure.
Gonzalez RR; Zweig S; Rao J; Block R; Greene LW
Endocr Pract; 2007; 13(4):417-23. PubMed ID: 17669721
[TBL] [Abstract][Full Text] [Related]
40. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients.
Holstein A; Hammer C; Hahn M; Kulamadayil NS; Kovacs P
Expert Opin Drug Saf; 2010 Sep; 9(5):675-81. PubMed ID: 20553106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
